BOTHELL, Wash.--(BUSINESS WIRE)--
Seattle Genetics, Inc. (SGEN) today announced the appointment of Robin G. Taylor, M.B.A., Ph.D., as Chief Commercial Officer. Dr. Taylor brings 18 years of biotechnology and pharmaceutical company experience in the commercialization of oncology drugs, including significant marketing, launch and global product strategy roles at both Genentech/Roche and AstraZeneca. He contributed to several leading global brands, including TECENTRIQ® (atezolizumab), ALECENSA® (alectinib), AVASTIN® (bevacizumab) and HERCEPTIN® (trastuzumab).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190521005064/en/
Clay Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics, commented, “We are excited to welcome Robin to the executive management team as our first Chief Commercial Officer. He has demonstrated strong leadership and success in the global commercial development and strategic marketing of several oncology franchises, notably at Genentech/Roche. Robin will play a key role in extending our commercial execution across six ADCETRIS lymphoma indications, while preparing for the potential launch of enfortumab vedotin and leading our global commercialization strategy for possible future products, such as tucatinib.”
Dr. Taylor stated, “Seattle Genetics has an outstanding culture of innovation and scientific excellence with a broad late-stage pipeline focused on providing a significant benefit to cancer patients with high unmet need. I look forward to leading the Commercial organization to bring these exciting therapies to patients as the company transitions to a multi-product, global oncology company.”
Robin Taylor has extensive global development and commercialization oncology experience. Most recently, he served as Vice President, Immuno-Oncology Franchise Head, Oncology Business Unit at AstraZeneca, where he led global marketing and product teams for IMFINZI® (durvalumab), an immunotherapy approved for metastatic urothelial carcinoma, and Stage III unresectable non-small cell lung cancer. Prior to joining AstraZeneca, Dr. Taylor served in roles of increasing responsibility at Genentech, a Member of the Roche Group, from 2001 to 2018. Most recently, he served as Vice President, Cancer Immunotherapy Franchise Head, Global Product Strategy, responsible for the global development and launch of TECENTRIQ across multiple indications. He received a Doctor of Philosophy, Molecular and Medical Genetics from University of Toronto, a Masters of Business Administration from University of California Berkeley, and a Bachelor of Science degree from University of British Columbia.
About Seattle Genetics
Seattle Genetics, Inc. is an emerging multi-product, global biotechnology company that develops and commercializes transformative therapies targeting cancer to make a meaningful difference in people’s lives. ADCETRIS® (brentuximab vedotin) utilizes the company’s industry-leading ADC technology and is currently approved for the treatment of multiple CD30-expressing lymphomas. Beyond ADCETRIS, the company has established a pipeline of novel targeted therapies at various stages of clinical testing, including three in ongoing pivotal trials for solid tumors. Enfortumab vedotin for metastatic urothelial cancer and tisotumab vedotin for metastatic cervical cancer utilize our proprietary ADC technology. Tucatinib, a small molecule tyrosine kinase inhibitor, is in a pivotal trial for HER2-positive metastatic breast cancer. In addition, we are leveraging our expertise in empowered antibodies to build a portfolio of proprietary immuno-oncology agents in clinical trials targeting hematologic malignancies and solid tumors. The company is headquartered in Bothell, Washington, and has a European office in Switzerland. For more information on our robust pipeline, visit www.seattlegenetics.com and follow @SeattleGenetics on Twitter.
Certain of the statements made in this press release are forward looking, such as those, among others, relating to the company’s transition into a multi-product global oncology company, expectations regarding expansion of the commercial uses of ADCETRIS and advancement of the company’s late-stage oncology pipeline, including enfortumab vedotin, tisotumab vedotin and tucatinib and the company’s other product candidates and those of its licensees and collaborators; as well as other statements that are not historical facts. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with maintaining or increasing sales of ADCETRIS due to competition, unexpected adverse events, regulatory action, reimbursement, market adoption by physicians or other factors. The company may also be delayed in its planned clinical trial initiations, the enrollment in and conduct of its clinical trials, obtaining data from clinical trials, planned regulatory submissions, and regulatory approvals in each case for a variety of reasons including the difficulty and uncertainty of pharmaceutical product development, negative or disappointing clinical trial results, unexpected adverse events or regulatory discussions or actions and the inherent uncertainty associated with the regulatory approval process. More information about the risks and uncertainties faced by Seattle Genetics is contained under the caption “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 filed with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise except as required by applicable law.